Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl clinical trials

Explore recruiting previously untreated diffuse large b cell lymphoma dlbcl clinical trials.

Recruiting previously untreated diffuse large b cell lymphoma dlbcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Belgium, Poland, France, Germany, Spain, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Spain, Portugal, Netherlands, Hungary, Greece, Denmark +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl trials by city

Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Toronto Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Vancouver Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Montreal Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Calgary Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Edmonton Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Ottawa Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Winnipeg Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Quebec City Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Hamilton Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Kitchener Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in London Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Halifax Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in New York Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Los Angeles Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Chicago Previously Untreated Diffuse Large B Cell Lymphoma Dlbcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease